The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Egis competitive analysis

Loading summary...

Latest oppositions filed by Egis

Explore patent oppositions filed by Egis against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 18, 2025
EP3626270
New UseNOVARTISJul 8, 2024
EP3294283
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISOct 9, 2023
EP2959894
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISJul 11, 2023
EP2234617
Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICADec 31, 2021
EP2981271
Therapeutic Uses Of EmpagliflozinBOEHRINGER INGELHEIMAug 12, 2019

Latest patents of Egis opposed by its competitors

Explore Egis's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP2359815
Jan 8, 2020Compositions Comprising Amlodipine And Bisoprolol1
EP2344141
May 1, 2019Compositions Comrrising Amlodipine And Bisoprolol1

Latest PTAB cases involving Egis

Discover the latest PTAB cases involving Egis, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Egis with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
UNILEVER6190 - -
HENKEL5951891 -
KONINKLIJKE DOUWE EGBERTS3427 - -
THE PROCTER & GAMBLE161379 - 21